Table 2.
Survival analysis evaluating impact of stage and metastatic sites on cancer-specific survival among included stage III primary testicular germ cell tumor patients. Model 1 Harrell’s C 0.723. Model 2 Harrell’s C 0.714. Surveillance, Epidemiology, and End Results Program 2010–2015.
| HR | 95% CI | p-value | HR | 95% CI | p-value | HR | 95% CI | p-value | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Low | High | Low | High | Low | High | ||||||||
| Univariable | Multivariable Model 11 | Multivariable Model 21 | |||||||||||
| Age | 1.03 | 1.02 | 1.04 | <0.01 | 1.03 | 1.01 | 1.04 | <0.01 | 1.03 | 1.01 | 1.04 | <0.01 | |
| Histology | NSGCT | REF | - | - | - | REF | - | - | - | REF | - | - | - |
| Seminoma | 0.92 | 0.61 | 1.38 | 0.68 | 0.59 | 0.13 | 0.38 | 0.92 | 0.73 | 0.47 | 1.14 | 0.16 | |
| Metastasis2 | Lung | 0.85 | 0.53 | 1.35 | 0.49 | - | - | - | - | 1.38 | 0.83 | 2.30 | 0.21 |
| Liver | 2.29 | 1.69 | 3.10 | <0.01 | - | - | - | - | 2.04 | 1.46 | 2.84 | <0.01 | |
| Bone | 1.94 | 1.29 | 2.92 | <0.01 | - | - | - | - | 1.62 | 1.04 | 2.53 | 0.03 | |
| Brain | 2.79 | 1.95 | 4.01 | <0.01 | - | - | - | - | 2.49 | 1.69 | 3.66 | <0.01 | |
| Stage | IIIA | REF | - | - | - | REF | - | - | - | - | - | - | - |
| IIIB | 2.74 | 1.28 | 5.86 | 0.01 | 3.10 | 1.44 | 6.66 | <0.01 | - | - | - | - | |
| IIIC | 5.63 | 3.12 | 10.17 | <0.01 | 5.17 | 2.83 | 9.42 | <0.01 | - | - | - | - | |
| III NOS | 1.82 | 0.92 | 3.60 | 0.08 | 1.64 | 0.82 | 3.27 | 0.16 | - | - | - | - | |
1
Multivariable Cox-proportional hazards models also adjusted for race, diagnosis year, laterality, and presence of lymphovascular invasion.
HR = hazard ratio, 95% CI = 95% confidence interval
2
Reference group for each organ site corresponds to the lack of involvement of the corresponding organ